Background Among patients with non–small-cell lung cancer (NSCLC), MET exon 14
skipping mutations occur in 3 to 4% and MET amplifications occur in 1 to 6%. Capmatinib, a …

9004 Background: Capmatinib is a highly potent and selective MET inhibitor. Previous data
of GEOMETRY mono-1 study showed a clinically meaningful overall response rate (ORR) …

Introduction: Activation of the MET pathway through MET amplifications or mutations is
present in 3–4% of stage IV non-squamous non-small cell lung cancers (NSCLC). High MET …

Introduction Capmatinib is approved for MET exon 14–altered NSCLC on the basis of
activity in targeted therapy–naive patients. We conducted a phase 2 study to assess the …

Abstract Treatment of advanced non-small cell lung cancer (NSCLC) has radically improved
in the last years due to development and clinical approval of highly effective agents …

Purpose: The selective MET inhibitor capmatinib is being investigated in multiple clinical
trials, both as a single agent and in combination. Here, we describe the preclinical data of …

Background Dysregulation of receptor tyrosine kinase MET by various mechanisms occurs
in 3%–4% of non-small-cell lung cancer (NSCLC) and is associated with unfavorable …

Purpose MET dysregulation occurs in up to 26% of non–small-cell lung cancers (NSCLCs)
after epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor (TKI) treatment …

MET exon 14 skipping mutation (MET∆ ex14) is present about 3% of non-small cell lung
cancers (NSCLCs). NSCLC patients with MET∆ ex14 are characterized by an average age …

METex14 skipping mutations occur in about 3–4% of lung adenocarcinoma patients and 1–
2% of patients with other lung cancer histology. The MET receptor tyrosine kinase and its …